Literature DB >> 10739661

Preferential expression of NuMA in the nuclei of proliferating cells.

P Taimen1, M Viljamaa, M Kallajoki.   

Abstract

Nuclear mitotic apparatus protein (NuMA) has an indispensable function in normal mitosis as an organizer of the mitotic spindle. NuMA is a prominent component of interphase cell nuclear matrix but its role during interphase is largely unknown. We examined the presence of NuMA in several human tissues. The majority of cells were positive for NuMA but a few negative cell types were found, including spermatozoa, superficial keratinocytes, neutrophil granulocytes, syncytiotrophoblasts, and some neurons, fibroblasts, and smooth and skeletal muscle cells. We further investigated the presence of NuMA in a cultured estrogen-dependent human breast cancer cell line and observed the disappearance of nuclear NuMA in the quiescent cells. The percentage of NuMA-positive cells diminished from an initial approximately 100 to 60% during 6 days of culture. The presence of NuMA correlated positively with the presence of proliferation marker Ki-67 antigen and negatively with the culture time, confluence, and size of the cell islets. These results show that some nonproliferating, highly differentiated cell types lack NuMA and that cells may lose their NuMA without dramatic effects on the nuclear shape. This suggests that NuMA may be a nonessential component of the interphase nucleus. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739661     DOI: 10.1006/excr.2000.4799

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Inhibition of protein 4.1 R and NuMA interaction by mutagenization of their binding-sites abrogates nuclear localization of 4.1 R.

Authors:  Subhendra N Mattagajasingh; Shu-Ching Huang; Edward J Benz
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

2.  Association of the NuMA region on chromosome 11q13 with breast cancer susceptibility.

Authors:  Stefan Kammerer; Richard B Roth; Carolyn R Hoyal; Richard Reneland; George Marnellos; Marion Kiechle; Ulrike Schwarz-Boeger; Lyn R Griffiths; Florian Ebner; Joachim Rehbock; Charles R Cantor; Matthew R Nelson; Andreas Braun
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

3.  Modulation of gene expression in MHCC97 cells by interferon alpha.

Authors:  Wei-Zhong Wu; Hui-Chuan Sun; Lu Wang; Jie Chen; Kang-Da Liu; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

4.  Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance.

Authors:  Branka Bonaci-Nikolic; Sladjana Andrejevic; Mirjana Bukilica; Ivana Urosevic; Milos Nikolic
Journal:  J Clin Immunol       Date:  2006-08-29       Impact factor: 8.317

5.  NuMA influences higher order chromatin organization in human mammary epithelium.

Authors:  Patricia C Abad; Jason Lewis; I Saira Mian; David W Knowles; Jennifer Sturgis; Sunil Badve; Jun Xie; Sophie A Lelièvre
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

6.  NMP22 is predictive of recurrence in high-risk superficial bladder cancer patients.

Authors:  Paul Lau; Joseph L Chin; Stephen Pautler; Hassan Razvi; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

7.  Over Expression of NANOS3 and DAZL in Human Embryonic Stem Cells.

Authors:  Sarita Panula; Ahmed Reda; Jan-Bernd Stukenborg; Cyril Ramathal; Meena Sukhwani; Halima Albalushi; Daniel Edsgärd; Michiko Nakamura; Olle Söder; Kyle E Orwig; Shinya Yamanaka; Renee A Reijo Pera; Outi Hovatta
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

8.  NuMA overexpression in epithelial ovarian cancer.

Authors:  Anke Brüning-Richardson; Jaqueline Bond; Rawiah Alsiary; Julie Richardson; David A Cairns; Luci McCormac; Richard Hutson; Philip A Burns; Nafisa Wilkinson; Geoff D Hall; Ewan E Morrison; Sandra M Bell
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.